{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-24-000004","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.103385+00:00","generated_at":"2026-06-06T03:59:13.785433+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biogen Q4 revenue $2.4B, GAAP EPS $1.71; 2024 Non-GAAP EPS guidance $15-$16","bullets":["Q4 2023 revenue $2.4B (-6% YoY); GAAP EPS $1.71 vs $3.79; Non-GAAP EPS $2.95 vs $4.05","Full year 2023 revenue $9.8B (-3% YoY); GAAP EPS $7.97 vs $20.87; Non-GAAP EPS $14.72 vs $17.67","EPS negatively impacted by $0.35 from ADUHELM closeout costs; LEQEMBI co-promotion announced","2024 guidance: Non-GAAP EPS $15.00-$16.00 (~5% growth vs 2023); revenue expected down low- to mid-single digit","SKYCLARYS launched with ~1,000 patients; ZURZUVAE postpartum depression launch; 'Fit for Growth' $1B gross savings by 2025"],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-24-000004","json":"https://secwatch.observer/filing/0000875045-24-000004.json","markdown":"https://secwatch.observer/filing/0000875045-24-000004.md","text":"https://secwatch.observer/filing/0000875045-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/biib-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:59:13.785433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"046bfc91937ee2872a9f34493f3737b6940e470c","claim":"BIOGEN INC. reported fourth quarter 2023 results: revenue $2.4 billion, EPS GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95.","evidence_excerpt":"Fourth quarter 2023 revenue $2.4 billion; GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"Revenue","value":"$2.4 billion"},{"label":"EPS","value":"GAAP diluted EPS $1.71; Non-GAAP diluted EPS $2.95"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4249ee395e29742f4421795d09cb06b829651d04","claim":"BIOGEN INC. reported full year 2024 results: revenue total revenue to decline by a low- to mid-single digit percentage vs. 2023, EPS Non-GAAP EPS of $15.00 to $16.00. Guidance initiated.","evidence_excerpt":"Full year 2024 financial guidance: Non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point • Expect total revenue to decline by a low- to mid-single digit percentage vs. 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"total revenue to decline by a low- to mid-single digit percentage vs. 2023"},{"label":"EPS","value":"Non-GAAP EPS of $15.00 to $16.00"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"cd103309dc7942c8193d8bdd7e3b4cdc67050de0","claim":"BIOGEN INC. reported full year 2023 results: revenue $9.8 billion, EPS GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72.","evidence_excerpt":"Full year 2023 revenue $9.8 billion; GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504524000004/0000875045-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$9.8 billion"},{"label":"EPS","value":"GAAP diluted EPS $7.97; Non-GAAP diluted EPS $14.72"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}